Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ADORA2A | P29274 | 1/20 | 0.32 |
| ▸ | ADORA1 | P30542 | 1/20 | 0.32 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.32 |
| ▸ | HPGD | P15428 | 2/20 | 0.32 |
| ▸ | MEN1 | O00255 | 1/20 | 0.32 |
| ▸ | THRB | P10828 | 1/20 | 0.32 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.32 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.31 |
| ▸ | LMNA | P02545 | 1/20 | 0.31 |
| ▸ | HTT | P42858 | 1/20 | 0.31 |
| ▸ | MAPT | P10636 | 1/20 | 0.30 |
| ▸ | TP53 | P04637 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL23498451 | 0.93 | ADORA2A (0.35) | ADORA2AADORA1ALDH1A1HPGDMEN1 | |
| SCHEMBL23498456 | 0.93 | ADORA2A (0.35) | ADORA2AADORA1ALDH1A1HPGDMEN1 | |
| SCHEMBL29998011 | 0.89 | MEN1 (0.35) | ADORA2AADORA1ALDH1A1HPGDMEN1 | |
| SCHEMBL25066141 | 0.89 | MEN1 (0.35) | ADORA2AADORA1ALDH1A1HPGDMEN1 | |
| SCHEMBL23498630 | 0.82 | MEN1 (0.37) | ADORA2AADORA1ALDH1A1HPGDMEN1 | |
| SCHEMBL23498626 | 0.82 | MEN1 (0.37) | ADORA2AADORA1ALDH1A1HPGDMEN1 | |
| SCHEMBL29998100 | 0.82 | TSHR (0.36) | ADORA2AADORA1ALDH1A1HPGDMEN1 | |
| SCHEMBL25066142 | 0.82 | TSHR (0.36) | ADORA2AADORA1ALDH1A1HPGDMEN1 | |
| SCHEMBL29997926 | 0.81 | ALDH1A1 (0.32) | ALDH1A1HPGDMEN1THRBKMT2A | |
| SCHEMBL24391229 | 0.80 | ALDH1A1 (0.33) | ALDH1A1HPGDMEN1THRBKMT2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230057568-A1 | COMPOUNDS FOR TREATING FAMILIAL DYSAUTONOMIA | PTC THERAPEUTICS, INC. (US) | 2023-02-23 | — | — | US | disclosed |
| EP-4072677-A1 | COMPOUNDS FOR TREATING FAMILIAL DYSAUTONOMIA | PTC Therapeutics, Inc. (US) | 2022-10-19 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230057568-A1 | COMPOUNDS FOR TREATING FAMILIAL DYSAUTONOMIA | SNRPB2, SYNCRIP, HNRNPUL2 | ADORA2A 1365/4885ADORA1 2493/4885ALDH1A1 2146/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.